This filing removes a key procedural overhang for the second tranche placement, but provides no new business or financial information. Monitor for the actual closing of the second tranche placement and any subsequent Nasdaq filings (F-6, prospectus) that would disclose pricing and total proceeds. The stock may trade on the removal of uncertainty, but the fundamental thesis remains unchanged until pipeline data is released.
Price Chart
Executive Summary
Radiopharm Theranostics reported that all 14 resolutions at its September 11, 2026 General Meeting were carried by poll, including ratification of prior share placements, approval of a second tranche placement, and issuance of shares and options to directors and the CEO. The overwhelming approval (94-99% 'for' votes) removes uncertainty around the company's capital raising plans, clearing the path for the second tranche placement and related equity issuances. For a $30M market cap company, this is a routine procedural filing that confirms shareholder support for previously announced financing, with no new financial data or business updates provided.
Key Facts
- All 14 resolutions at the General Meeting were carried by poll.
- Resolution 1a (ratification of First Tranche Placement Shares) passed with 97.33% 'for' votes.
- Resolution 2 (approval to issue Second Tranche Placement Shares) passed with 96.81% 'for' votes.
- Resolutions 8a-8d (approval to issue SPP Shares and Options to four directors/CEO) all passed with 94-95% 'for' votes.
- The filing confirms shareholder approval for previously announced capital raising, including placements and options.
- No financial results, business updates, or guidance were provided in this filing.
Financial Impact
Removes shareholder approval risk for second tranche placement and related equity issuances; no dollar amounts disclosed.
Risk Factors
- Dilution from the approved second tranche placement and option issuances is now confirmed.
- No new business updates or clinical data were provided, leaving the investment thesis dependent on future milestones.
- The company has a $30M market cap and is pre-revenue, making it highly sensitive to financing and pipeline events.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-098976 |
| Document: ea0305226-6k_radiopharm.htm | 0001213900-26-098976 |
| Document: 0001213900-26-098976-index-headers.html | 0001213900-26-098976 |
| Document: 0001213900-26-098976-index.html | 0001213900-26-098976 |
| Document: 0001213900-26-098976.txt | 0001213900-26-098976 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9600 | awaiting T+5 | — | $0.9000 (−6.25%) |
Oct 26, 2026 1d ago | 6-K | $0.9960 | awaiting T+5 | — | $0.9000 (−9.64%) |
Oct 20, 2026 7d ago | 6-K | $0.9900 $0.9000 | ▼ −9.09% | ▼ −9.17% | $0.9000 (−9.09%) |
Oct 14, 2026 13d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9000 (−16.67%) |
Oct 5, 2026 22d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9000 (−29.13%) |
Oct 1, 2026 26d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9000 (−39.19%) |
Sep 30, 2026 27d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9000 (−44.44%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9000 (+42.74%) |
Sep 22, 2026 5w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9000 (−45.45%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9000 (−55.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers